Medical diagnostics startup JaxBio Technologies, based in Netanya, Israel, was awarded a $2.73 million grant by the European Innovation Council (EIC) Accelerator.
This funding came with the possibility of future blended financing, meaning that another €9.1 million may come from the EU and another €9.1 million from private investors.
The company plans to utilise the money to build its diagnostics platform, extend clinical programmes, and develop a blood test that will make lung cancer diagnosis and treatment easier, faster, and more accurate.
Read also- Singapore-Based Dr Clear Aligners Raises $8 Million in Series A Round Funding
Under the direction of Dr. Shahar Zirkin, the company’s founder and CEO, JaxBio is creating a blood test for accurate cancer and other disease diagnosis.
Read also- India-Based Ninecamp Secures $2 Million in Seed Round Funding
Its liquid biopsy method improves monitoring, therapy prediction, and diagnosis by detecting hundreds of cancer biomarkers in blood at a low cost and great sensitivity.
When time is of the essence, this lab technique yields results the next day, allowing healthcare practitioners and patients to make quicker, more informed decisions.
About JaxBio Technologies
JaxBio‘s blood test technology is simplifying, speeding up, and improving cancer diagnosis and management. The novel blood test outperforms liquid biopsies and other procedures. Due to its great sensitivity, low cost, and simplicity, they can give faster, more accurate results. Improved cancer screening and early detection allow healthcare practitioners and patients to make faster, more informed decisions.
